The global Hepatic Encephalopathy Therapeutics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hepatic Encephalopathy Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
ASKA Pharmaceutical
COSMO Pharmaceuticals
Fresenius Kabi
Mallinckrodt Pharmaceuticals
Lupin
Salix Pharmaceuticals
Teva Pharmaceutical
Bausch Health
Segment by Type
Kits
Reagents
Instruments
Segment by Application
Acute Liver Failure
Portal Systemic Bypass without Liver Disease
Liver Cirrhosis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hepatic Encephalopathy Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatic Encephalopathy Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Kits
1.2.3 Reagents
1.2.4 Instruments
1.3 Market by Application
1.3.1 Global Hepatic Encephalopathy Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Acute Liver Failure
1.3.3 Portal Systemic Bypass without Liver Disease
1.3.4 Liver Cirrhosis
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatic Encephalopathy Therapeutics Market Perspective (2018-2029)
2.2 Hepatic Encephalopathy Therapeutics Growth Trends by Region
2.2.1 Global Hepatic Encephalopathy Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hepatic Encephalopathy Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Hepatic Encephalopathy Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Hepatic Encephalopathy Therapeutics Market Dynamics
2.3.1 Hepatic Encephalopathy Therapeutics Industry Trends
2.3.2 Hepatic Encephalopathy Therapeutics Market Drivers
2.3.3 Hepatic Encephalopathy Therapeutics Market Challenges
2.3.4 Hepatic Encephalopathy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatic Encephalopathy Therapeutics Players by Revenue
3.1.1 Global Top Hepatic Encephalopathy Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Hepatic Encephalopathy Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Hepatic Encephalopathy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hepatic Encephalopathy Therapeutics Revenue
3.4 Global Hepatic Encephalopathy Therapeutics Market Concentration Ratio
3.4.1 Global Hepatic Encephalopathy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Therapeutics Revenue in 2022
3.5 Hepatic Encephalopathy Therapeutics Key Players Head office and Area Served
3.6 Key Players Hepatic Encephalopathy Therapeutics Product Solution and Service
3.7 Date of Enter into Hepatic Encephalopathy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hepatic Encephalopathy Therapeutics Breakdown Data by Type
4.1 Global Hepatic Encephalopathy Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Hepatic Encephalopathy Therapeutics Forecasted Market Size by Type (2024-2029)
5 Hepatic Encephalopathy Therapeutics Breakdown Data by Application
5.1 Global Hepatic Encephalopathy Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Hepatic Encephalopathy Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Hepatic Encephalopathy Therapeutics Market Size (2018-2029)
6.2 North America Hepatic Encephalopathy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hepatic Encephalopathy Therapeutics Market Size by Country (2018-2023)
6.4 North America Hepatic Encephalopathy Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hepatic Encephalopathy Therapeutics Market Size (2018-2029)
7.2 Europe Hepatic Encephalopathy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hepatic Encephalopathy Therapeutics Market Size by Country (2018-2023)
7.4 Europe Hepatic Encephalopathy Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hepatic Encephalopathy Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Hepatic Encephalopathy Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hepatic Encephalopathy Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Hepatic Encephalopathy Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hepatic Encephalopathy Therapeutics Market Size (2018-2029)
9.2 Latin America Hepatic Encephalopathy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hepatic Encephalopathy Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Hepatic Encephalopathy Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatic Encephalopathy Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Hepatic Encephalopathy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hepatic Encephalopathy Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Hepatic Encephalopathy Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ASKA Pharmaceutical
11.1.1 ASKA Pharmaceutical Company Detail
11.1.2 ASKA Pharmaceutical Business Overview
11.1.3 ASKA Pharmaceutical Hepatic Encephalopathy Therapeutics Introduction
11.1.4 ASKA Pharmaceutical Revenue in Hepatic Encephalopathy Therapeutics Business (2018-2023)
11.1.5 ASKA Pharmaceutical Recent Development
11.2 COSMO Pharmaceuticals
11.2.1 COSMO Pharmaceuticals Company Detail
11.2.2 COSMO Pharmaceuticals Business Overview
11.2.3 COSMO Pharmaceuticals Hepatic Encephalopathy Therapeutics Introduction
11.2.4 COSMO Pharmaceuticals Revenue in Hepatic Encephalopathy Therapeutics Business (2018-2023)
11.2.5 COSMO Pharmaceuticals Recent Development
11.3 Fresenius Kabi
11.3.1 Fresenius Kabi Company Detail
11.3.2 Fresenius Kabi Business Overview
11.3.3 Fresenius Kabi Hepatic Encephalopathy Therapeutics Introduction
11.3.4 Fresenius Kabi Revenue in Hepatic Encephalopathy Therapeutics Business (2018-2023)
11.3.5 Fresenius Kabi Recent Development
11.4 Mallinckrodt Pharmaceuticals
11.4.1 Mallinckrodt Pharmaceuticals Company Detail
11.4.2 Mallinckrodt Pharmaceuticals Business Overview
11.4.3 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Therapeutics Introduction
11.4.4 Mallinckrodt Pharmaceuticals Revenue in Hepatic Encephalopathy Therapeutics Business (2018-2023)
11.4.5 Mallinckrodt Pharmaceuticals Recent Development
11.5 Lupin
11.5.1 Lupin Company Detail
11.5.2 Lupin Business Overview
11.5.3 Lupin Hepatic Encephalopathy Therapeutics Introduction
11.5.4 Lupin Revenue in Hepatic Encephalopathy Therapeutics Business (2018-2023)
11.5.5 Lupin Recent Development
11.6 Salix Pharmaceuticals
11.6.1 Salix Pharmaceuticals Company Detail
11.6.2 Salix Pharmaceuticals Business Overview
11.6.3 Salix Pharmaceuticals Hepatic Encephalopathy Therapeutics Introduction
11.6.4 Salix Pharmaceuticals Revenue in Hepatic Encephalopathy Therapeutics Business (2018-2023)
11.6.5 Salix Pharmaceuticals Recent Development
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Detail
11.7.2 Teva Pharmaceutical Business Overview
11.7.3 Teva Pharmaceutical Hepatic Encephalopathy Therapeutics Introduction
11.7.4 Teva Pharmaceutical Revenue in Hepatic Encephalopathy Therapeutics Business (2018-2023)
11.7.5 Teva Pharmaceutical Recent Development
11.8 Bausch Health
11.8.1 Bausch Health Company Detail
11.8.2 Bausch Health Business Overview
11.8.3 Bausch Health Hepatic Encephalopathy Therapeutics Introduction
11.8.4 Bausch Health Revenue in Hepatic Encephalopathy Therapeutics Business (2018-2023)
11.8.5 Bausch Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
ASKA Pharmaceutical
COSMO Pharmaceuticals
Fresenius Kabi
Mallinckrodt Pharmaceuticals
Lupin
Salix Pharmaceuticals
Teva Pharmaceutical
Bausch Health
*If Applicable.